Back to Results

Vyne Therapeutics Inc (VYNE)

Vyne Therapeutics Inc. is a clinical-stage biopharmaceutical company listed on the NASDAQ under the ticker VYNE. The company focuses on developing treatments for chronic inflammatory and immune-mediated conditions. Its lead program is repibresib gel (VYN201), a topical small-molecule BET inhibitor designed to act locally with low systemic exposure, and it is also advancing VYN202, an oral BD2-selective BET inhibitor being evaluated in a Phase 1b trial for immune-mediated inflammatory conditions. Founded in 2003 and based in Stewartsville, New Jersey, the company adopted the Vyne Therapeutics name in September 2020 after previously operating as Menlo Therapeutics Inc.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-VYNE
$0.61
-28.0% Downside
Overvalued
$2
135.8% Upside
Bargain
Fair
0.0%
1.1x
62.3x
26.942 M
3.355 M
0.0%
91.6%
-30.1
118.5%
Valuation • Fair Value

Vyne Therapeutics Inc (NASDAQ-VYNE) Fair Value by Valuation Model

Review the available estimates for Vyne Therapeutics Inc (NASDAQ-VYNE), including Comps Fair Value.

Primary Valuation Read

Fair Value

$0.61

Estimated downside of 28.0% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$0.61

Comparable-company valuation reference.

Analyst Price Target

$2

Analysts imply upside of 135.8%.

How to read these valuation models

Use the 4 available valuation references for Vyne Therapeutics Inc (NASDAQ-VYNE) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Vyne Therapeutics Inc (NASDAQ-VYNE)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

454 K

Current operating scale indicator.

Revenue Forecast

612.75 K

Forward revenue estimate.

EBITDA

-24.345 M

Current operating profitability reference.

EBITDA Forecast

-50.7 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Vyne Therapeutics Inc (NASDAQ-VYNE) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Vyne Therapeutics Inc (NASDAQ-VYNE)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

4

Mid-range quality score.

Altman Z-Score

-30.1

Lower score that deserves closer risk review.

FCF / Net Income

118.5%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Vyne Therapeutics Inc (NASDAQ-VYNE). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Dividend Profile for Vyne Therapeutics Inc (NASDAQ-VYNE)

Review the dividend metrics currently supported by the latest data.

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

The latest data indicates no current dividend yield for Vyne Therapeutics Inc (NASDAQ-VYNE). No upcoming dividend amount or event date is currently available.

Stock Forecast • Technical Outlook

Vyne Therapeutics Inc (NASDAQ-VYNE) Stock Forecast & Technical Outlook

Review Vyne Therapeutics Inc (NASDAQ-VYNE) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Vyne Therapeutics Inc (NASDAQ-VYNE) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Vyne Therapeutics Inc (NASDAQ-VYNE) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Vyne Therapeutics Inc (NASDAQ-VYNE) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Vyne Therapeutics Inc (NASDAQ-VYNE) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Sell

The monthly technical read for Vyne Therapeutics Inc (NASDAQ-VYNE) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Vyne Therapeutics Inc (NASDAQ-VYNE)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Buy

Based on the available recommendation mix, Vyne Therapeutics Inc (NASDAQ-VYNE) has a Buy consensus, with 1 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 1
Sell 0
FAQ • Fast Investor Answers

Vyne Therapeutics Inc (NASDAQ-VYNE) Stock FAQ

Data-supported answers about Vyne Therapeutics Inc (NASDAQ-VYNE), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$0.61
Estimated downside 28.0%
Valuation Rating
Overvalued
Estimated downside of 28.0%
Analyst Target
$2
Implied upside 135.8%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Vyne Therapeutics Inc (NASDAQ-VYNE) is $0.61. This implies an estimated downside of 28.0% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 28.0% versus the current market price.

The available analyst price target for Vyne Therapeutics Inc (NASDAQ-VYNE) is $2. The analyst target implies estimated upside of 135.8%.

The current financial health read for Vyne Therapeutics Inc (NASDAQ-VYNE) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The latest available data indicates no current dividend yield for Vyne Therapeutics Inc (NASDAQ-VYNE).

The current market capitalization listed for Vyne Therapeutics Inc is 26.942 M.

The current enterprise value listed for Vyne Therapeutics Inc is 3.355 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Vyne Therapeutics Inc is NASDAQ-VYNE, and the stock is listed on NASDAQ.

Vyne Therapeutics Inc (NASDAQ-VYNE) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Vyne Therapeutics Inc is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Vyne Therapeutics Inc is 91.6%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,043 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 648.7 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 372.3 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 269.8 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 175.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 159.2 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 127.2 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 102 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.9 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.536 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 46.053 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.268 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.639 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 30.107 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.733 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.616 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Overvalued Market Cap 12.702 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.456 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.639 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.564 B